Comparative Clinical Pathology

, Volume 20, Issue 2, pp 183–186 | Cite as

Reactivation of latent Toxoplasma gondii in immunocompromised cancer patients

  • Mohamad Nidal Khabaz
  • Layla Elkhateeb
  • Jamil Al-Alami
Original Article

Abstract

Active Toxoplasma gondii infection in cancer patients undergoing anticancer chemotherapy was evaluated using both enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) techniques. Ninety-nine cancer patients were studied. Sixty seven of those patients were under cancer chemotherapy treatment, 41 (61.2%) of which were found to be ELISA immunoglobulin g (IgG) positive and five (7.5%) were PCR positive. On the other hand, none of the 32 untreated cancer patients was found to be PCR positive although 22 (68.7%) of them were ELISA IgG positive. These findings suggest the possibility that treatment with immunosuppressive agents predisposed cancer patients to reactivation of T. gondii infection.

Keywords

Toxoplasma gondii parasitemia Immunocompromised cancer patients Chemotherapy 

References

  1. Al-Omari OM (1994) Prevalence of antibodies to Toxoplasma gondii among blood donors in Abha, Asir region, south-western Saudi Arabia. J Egypt Public Health Assoc 69:77–88Google Scholar
  2. Black MW, Boothroyd JC (2000) Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev 64:607–623PubMedCrossRefGoogle Scholar
  3. Burg JL, Grover CM, Pouletty P, Boothroyd JC (1989) Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. J Clin Microbiol 8:1787–1792Google Scholar
  4. Dubey JP, Lindsay DS, Speer CA (1998) Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 11:267–299PubMedGoogle Scholar
  5. Embil JA, Covert AA, Howes WJ, Tanner CE, Staudt M (1985) Visualization of Toxoplasma gondii in the cerebrospinal fluid of a child with a malignant astrocytoma. Can Med Assoc J 133:213–214PubMedGoogle Scholar
  6. Ferreira MS, Borges AS (2002) Some aspects of protozoan infections in immunocompromised patients: a review. Mem Inst Oswaldo Cruz 97:443–457PubMedGoogle Scholar
  7. Gleason TH, Hamlin WB (1974) Disseminated toxoplasmosis in the compromised host: report of five cases. Arch Intern Med 134:1059–1062PubMedCrossRefGoogle Scholar
  8. Hakes TB, Armstrong D (1983) Toxoplasmosis: problems in diagnosis and treatment. Cancer 52:1535–1540PubMedCrossRefGoogle Scholar
  9. Hoghooghi-Rad N, Afraa M (1993) Prevalence of toxoplasmosis in humans and domestic animals in Ahwaz, capital of Khoozestan, south-west Iran. J Trop Med Hyg 96:163–168PubMedGoogle Scholar
  10. Ho-Yen DO, Joss AW, Smyth ET, Baird D, Chaterton JM (1992) Use of polymerase chain reaction to detect Toxoplasma gondii in human blood samples. J Clin Pathol 45:910–613PubMedCrossRefGoogle Scholar
  11. Israelski DM, Remington JS (1993) Toxoplasmosis in patients with cancer. Clin Infect Dis 17:423–435Google Scholar
  12. Kusne S, Dummer JS, Ho M, Whiteside T, Rabin BS, Makowka L, Esquivel CO, Starzi TE (1986) Self-limited Toxoplasma parasitemia after liver transplantation. Transplantation 44:457–458Google Scholar
  13. Mechain B, Jean-Franc Y, Garin O, Robert-Gangneux F, Dupouy-Camet J, Derouin F (2000) Lack of utility of specific immunoglobulin G antibody avidity for serodiagnosis of reactivated toxoplasmosis in immunocompromised patients. Clin Diagn Lab Immunol 7:703–705PubMedGoogle Scholar
  14. Pinon JM, Foudrinier F, Mougeot G, Marx C, Aubert D, Toupance O, Niel G, Danis M, Camerlynck P, Remy G, Frottier J, Jolly D, Bessieres MH, Lenoble DR, Bonhomme A (1995) Evaluation of risk and diagnostic value of quantitative assays for anti-Toxoplasma gondii immunoglobulin A (IgA), IgE and IgM and analytical study of specific IgG in immunodeficient patients. J Clin Microbiol 33:878–884PubMedGoogle Scholar
  15. Raz R, Nishri Z, Mates A, Sartani G, Hadad N, Reichman N, Miron D, Flatau E (1993) Seroprevalence of antibodies against Toxoplasma gondii among two rural populations in northern Israel. Isr J Med Sci 29:636–639PubMedGoogle Scholar
  16. Sluiters JF, Balk AH, Essed CE, Mochtar B, Weimar W, Simoons ML, Ijzerman EP (1989) Indirect enzyme-linked immunoassay for immunoglobulin G and four immunoassays for immunoglobulin M to Toxoplasma gondii in a series of heart transplant recipients. J Clin Microbiol 27:529–535PubMedGoogle Scholar
  17. Strannegard O, Holm SE, Weinfeld A, Westin J (1973) Serologic studies of infections in patients with hematologic malignancy. Scand J Infect Dis 5:181–186PubMedGoogle Scholar
  18. Wilson M, Remington JS, Clavet C, Varney G, Press C, Ware D, and the FDA toxoplasmosis Ad Hoc working group (1997) Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol 35:3112–3115PubMedGoogle Scholar
  19. Yazar S, Yaman O, Eser B, Altuntas F, Kurnaz F, Sahin I (2004) Investigation of anti-Toxoplasma gondii antibodies in patients with neoplasia. J Med Microbiol 53:1183–1186PubMedCrossRefGoogle Scholar
  20. Yuan Z, Gao S, Liu Q, Xia X, Liu X, Liu B, Hu R (2007) Toxoplasma gondii antibodies in cancer patients. Cancer Lett 254:71–74PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2010

Authors and Affiliations

  • Mohamad Nidal Khabaz
    • 1
  • Layla Elkhateeb
    • 2
  • Jamil Al-Alami
    • 3
  1. 1.Department of Pathology, Faculty of MedicineJordan University of Science and TechnologyIrbidJordan
  2. 2.Department of Medical Laboratory Sciences, Faculty of Health Allied sciencesJordan University of Science and TechnologyIrbidJordan
  3. 3.Department of Molecular GeneticsShafallah Medical Genetics CenterDohaQatar

Personalised recommendations